Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aspirin plus clopidogrel Clear all
Not listed Phase 4 Interventional Results available

CYPRESS - CYPHER for Evaluating Sustained Safety

NCT00954707
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel & Aspirin, Prasugrel & Aspirin, Placebo & Aspirin
Drug
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
2,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 2, 2026, 12:44 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

NCT03787927
View directory record Official record
Conditions
Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
Interventions
Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (cold-stored 15 days), Aspirin, Clopidogrel
Drug
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Results available

Polypill in Acute Coronary Syndrome

NCT05514938
View directory record Official record
Conditions
Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions
Polypill, Usual Care (individual medications prescribed by primary cardiologist)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 12:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)

NCT02094755
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Blood draw only
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 2, 2026, 12:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

NCT03746782
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Flow Cytrometry; Thrombin Generation Assay
Diagnostic Test
Lead sponsor
CirQuest Labs, LLC
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 2, 2026, 12:44 AM EDT
Not listed No phase listed Observational

Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan

NCT03615846
View directory record Official record
Conditions
Platelet Aggregation, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Results available

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

NCT00621855
View directory record Official record
Conditions
Coronary Disease
Interventions
placebo, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 2, 2026, 12:44 AM EDT
Terminated Not applicable Interventional Results available

Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.

NCT02696226
View directory record Official record
Conditions
Aortic Valve Disorder
Interventions
SAVR Warfarin, SAVR Aspirin, TAVR Warfarin and clopidogrel, TAVR Aspirin and clopidogrel
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 4 Interventional Results available

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

NCT03718429
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
Interventions
Rivaroxaban 2.5 mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510
View directory record Official record
Conditions
Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Ticagrelor + Aspirin, Clopidogrel + Aspirin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 2, 2026, 12:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI

NCT02499666
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Percutaneous Coronary Intervention, Coronary stent, Clopidogrel
Procedure · Device · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 2, 2026, 12:44 AM EDT
Not listed No phase listed Observational

International PFO Consortium

NCT00859885
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack
Interventions
Antithrombotic treatment, percutaneous device closure of PFO
Drug · Device
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Springfield, Massachusetts • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 3 Interventional

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

NCT00714961
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Clopidogrel (SR25990), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
3,491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

NCT00249873
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 2, 2026, 12:44 AM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 12:44 AM EDT
Recruiting No phase listed Observational

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

NCT05907629
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
Interventions
MRI
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
28
States / cities
Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 2, 2026, 12:44 AM EDT
Terminated Phase 3 Interventional Results available

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Results available

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

NCT00357968
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 2, 2026, 12:44 AM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Clopidogrel on Incidence of Silent Brain Infarction

NCT04698031
View directory record Official record
Conditions
Silent Brain Infarction
Interventions
Clopidogrel treatment, Aspirin treatment
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 90 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 2, 2026, 12:44 AM EDT
Not listed Early Phase 1 Interventional

Lovaza's Effect on Clopidogrel in a Neuro Population

NCT01526824
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack
Interventions
omega-3 polyunsaturated fatty acids (Lovaza)
Dietary Supplement
Lead sponsor
Millard Fillmore Gates Hospital
Other
Eligibility
25 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 4 Interventional Results available

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

NCT02548650
View directory record Official record
Conditions
Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
Interventions
Vorapaxar, Clopidogrel, Aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 2, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Results available

Edoxaban in Peripheral Arterial Disease

NCT01802775
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
edoxaban, Clopidogrel, Aspirin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 2, 2026, 12:44 AM EDT